ストックスクリーナーアプリを入手
601.65
2.36%
-14.53
プレマーケット:
603.00
1.35
+0.22%
前日終値:
$616.18
開ける：
$619.07
24時間の取引高:
815.35K
Relative Volume:
0.97
時価総額：
$63.08B
収益：
$14.92B
当期純損益:
$4.42B
株価収益率:
14.66
EPS:
41.0422
ネットキャッシュフロー:
$3.79B
1週間 パフォーマンス:
-2.80%
1か月 パフォーマンス:
-15.84%
6か月 パフォーマンス:
-17.15%
1年 パフォーマンス:
+14.92%
1日の値動き範囲:
$601.22
$619.25
1週間の範囲:
$601.22
$640.82
52週間の値動き範囲:
$503.25
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
601.65 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
435.71 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
862.18 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.22 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.19 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-31 | 再開されました | Piper Sandler | Overweight |
| 2026-03-06 | 開始されました | Barclays | Overweight |
| 2026-01-07 | アップグレード | BofA Securities | Underperform → Buy |
| 2025-12-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 開始されました | HSBC Securities | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Regeneron-backed Parabilis rises on market debut (REGN:NASDAQ) - Seeking Alpha
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Parabilis Medicines Raises $670 Million in Initial Public Offering - Pharmaceutical Executive
How WHO’s Maftivimab Priority for Bundibugyo Trials At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) stock price, news, quote and history - Yahoo Finance Singapore
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak - Insider Monkey
Parabilis Medicines targets $2.3 billion valuation in upsized US IPO - marketscreener.com
Allergic Rhinitis Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight - Barchart.com
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities - Seeking Alpha
5 Best Healthcare Stocks to Buy with Highest Upside Potential - Insider Monkey
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Daiwa Securities Group Inc. Sells 2,058 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court - Law360
Regeneron Pharmaceuticals Inc stock (US7739031091): valuation metrics in focus after recent trading - AD HOC NEWS
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein - The National Law Review
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Alvotech targets J&J’s Simponi and Regeneron’s Eylea (ALVO) - Seeking Alpha
Cambridge biotech plans $450M IPO with Regeneron backing - The Business Journals
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics - Yahoo Finance
With Strong Cash Flow, Regeneron Pharmaceuticals Stock Poised to Rise? - Trefis
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
2026-06-04 | Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
CytomX expands collaboration with Regeneron - The Pharma Letter
Regeneron backed Parabilis seeks up to $476M in U.S. IPO - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold? - Yahoo! Finance Canada
Regeneron to present clinical data at diabetes and endocrine meetings By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by TD Asset Management Inc - MarketBeat
Regeneron to present clinical data at diabetes and endocrine meetings - Investing.com
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets - BioSpace
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO - The Manila Times
Obesity and ultra-rare bone disease data from Regeneron at June conferences - Stock Titan
Sound Shore Management Inc. CT Has $135.76 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
CytomX stock jumps on $37M Regeneron collaboration payment - Investing.com
Regeneron and CytomX extend cancer therapy partnership to $4bn deal - Pharmaceutical Technology
CIBC Asset Management Inc Acquires 10,329 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bank of New York Mellon Corp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strong Cash Yield: Is Regeneron Pharmaceuticals Stock A Buy? - Trefis
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
2.47%
大文字化:
|
ボリューム (24 時間):